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Mitochondrial metabolismComplex organisms may coordinate molecular responses to hypoxia by specialized avenues of communication
across multiple tissues, but these mechanisms are poorly understood. Plasma-based, extracellular microRNAs
have been described, yet their regulation and biological functions in hypoxia remain enigmatic. We found a
unique pattern of release of the hypoxia-inducible microRNA-210 (miR-210) from hypoxic and reoxygenated
cells. ThismicroRNA is also elevated in human plasma in physiologic and pathologic conditions of altered oxygen
demandanddelivery. ReleasedmiR-210 canbedelivered to recipient cells, and the suppressionof its direct target
ISCU and mitochondrial metabolism is primarily evident in hypoxia. To regulate these hypoxia-speciﬁc actions,
prolyl-hydroxylation of Argonaute 2 acts as a molecular switch that reciprocally modulates miR-210 release
and intracellular activity in source cells as well as regulates intracellular activity in recipient cells after miR-
210 delivery. Therefore, Argonaute 2-dependent control of released miR-210 represents a unique communica-
tion system that integrates the hypoxic response across anatomically distinct cells, preventing unnecessary activ-
ity of delivered miR-210 in normoxia while still preparing recipient tissues for incipient hypoxic stress and
accelerating adaptation.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hypoxic–ischemic and reoxygenation injury are associated with a
variety of complex human diseases and are leading causes of morbidity
andmortality, affecting every major organ system. Although poorly un-
derstood, hypoxic adaptation in a complex mammal may depend upon
close communication among anatomically distant tissues in order to
protect vital organs from incipient hypoxic stress. For example, remote
ischemic preconditioning (remote IPC) is a powerful innatemechanism
which prevents lethal ischemic injury by prior sub-lethal ischemia at
an anatomically distant site [1] and has been exploited in a number of
clinical settings [2]. Remote IPC and its associated applications may
rely upon release of endocrine factors from ischemic cells that initiatespital, New Research Building,
, USA. Tel.: +1 617 525 4844;
. This is an open access article underadaptive gene programs in recipient tissue [3], and a number of these
factors may be directly regulated by the master transcription factor
of hypoxia, HIF-α [4–6]. However, the full complement of such HIF-
dependent molecular effectors remains undeﬁned.
Previously, we reported that the hypoxia-inducible microRNA-210
(miR-210) controls such adaptive responses to hypoxia at the intracel-
lular level [7]. To do so, HIF-1α up-regulates expression of miR-210,
which then represses its direct target, the iron–sulfur cluster assembly
protein, ISCU. Consequently, deﬁcient ISCU expression reduces iron–
sulfur cluster integrity and thus represses key metabolic processes in-
cluding mitochondrial electron transport and the tricyclic acid (TCA)
cycle in favor of glycolysis. Additionally, miR-210 has been found to
down-regulate other related mitochondrial targets [8,9], thereby pro-
ducing a combinatorial effect on inhibiting electron transport andmito-
chondrial respiration. As a result, this metabolic shift, known as the
“Pasteur effect,” improves cell survival and function in acute hypoxia
while avoiding excessive generation of toxic reactive oxygen species
(ROS) [10] and thus preserving overall mitochondrial integrity and
function after the ischemic threat has ceased.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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bly secreted into the bloodstream at rest [11] and in response to tissue
injury and other pathological conditions [12–14]. Increases of plasma-
based expression of miR-210 have been reported in the context of var-
ious cancers, such as pancreatic [15], renal [16,17], and breast [18,19]
cancer, aswell as other systemic diseases [20–23]. Plasma-based, “circu-
lating”miRNAs may be protected from degradation by several comple-
mentary mechanisms including packaging in phospholipid bilayer-
encapsulated microvesicles or exosomes [24] and/or via the formation
of miRNA–protein complexes, such as those bound to the Argonaute 2
protein (AGO2) [25] or high density lipoprotein (HDL) [26]. In the set-
ting of microvesicle release, it has been reported that some miRNAs
are also complexed with AGO2, can be directly taken up by recipient
cells, and have been implicated in cellular functions important in certain
diseases [26–30] such as modulation of atherosclerotic lesions [31] and
tumor metastasis [32] in mice, to name a few examples. Yet, the molec-
ular regulation of the release and activity of extracellular miRNAs, espe-
cially in hypoxia, has been poorly characterized to date. Furthermore,
beyond its potential role as a biomarker, a speciﬁc function of miR-
210 as a circulating factor in hypoxia to communicate among distinct
tissues has not been fully explored.
In this report, we deﬁne released miR-210 as a highly regulated
effector communicating between hypoxic source tissue and recipient
cells. Moreover, we describe prolyl-hydroxylation of AGO2 as a pivotal
molecular switch that controls miR-210 release and miR-210 activity
upon uptake into recipient cells. These results augment our fundamen-
tal understanding of howdistant tissuesmay communicate via extracel-
lularmiRNAs in order to maintain precise control of hypoxic adaptation
across anatomically distinct cells.
2. Materials and methods
2.1. Cells, animals, and human reagents
Primary human pulmonary arterial endothelial cells (HPAECs),
human pulmonary arterial smooth muscle cells (HPASMCs), and normal
human lung ﬁbroblasts (NHLF) were commercially purchased (Lonza);
experiments were performed at passages 3–9. Human embryonic kidney
293 cells (HEK293) andHT-29 colon adenocarcinoma cellswere obtained
from ATCC. The generation of mmu-miR-210−/−mice was previously
described [33], and these mice were a generous gift from Dr. A. Bradley
and Dr. H. Prosser (Wellcome Trust, U.K.). The Harvard Center for Com-
parative Medicine approved the use of animals in these experiments.
2.2. Human participants
Written informed consent was obtained from all participants;
this conformed to the standards set by the latest revision of the Declara-
tion of Helsinki. Before study initiation, the Partners Human Research
Committee approved all protocols for human plasma study and collec-
tion. A case:control strategy was used in all comparisons. In the ﬁrst
case, as chosen from a larger, previously described cohort [34,35],
women of Andean descent at 36 weeks gestation with healthy preg-
nancies were compared — those living chronically at low altitude
(400 m, Santa Cruz, Bolivia) and those living at neighboring high al-
titude (3600 m–4100m, La Paz or El Alto, Bolivia). In the second case,
age-matched human subjects were chosen from the vascular medicine
research laboratory at the BrighamandWomen's Hospital and stratiﬁed
by the presence or absence of leg claudication and peripheral artery dis-
ease based on ankle:brachial index b0.90.
2.3. Exposure of cultured mammalian cells to conditions of hypoxia and
reoxygenation
Cells were cultured in standard non-hypoxic cell culture conditions
(20% O2, 5% CO2, with N2 balance at 37 °C). Alternatively, hypoxicconditions (0.2%–2% O2, 5% CO2, with N2 balance at 37 °C) were gener-
ated in a modular hypoxia chamber. Cells were exposed to either
normoxia (20% O2) or hypoxia (0.2% O2) for 24 and 48 h (e.g., HEK293
cells in DMEM media supplemented with 10% fetal calf serum, and
HPAECs in EGM-2 media with 5% fetal calf serum [Lonza]). To simulate
reoxygenation, cellswere exposed to hypoxia (either 24or 48h) follow-
ed by aspiration of culture media. Cells were then washed with PBS be-
fore adding fresh media followed by incubation for an additional 24 or
48 h in normoxia (20% O2).
2.4. MiRNA/AGO2 co-immunoprecipitation of conditioned media
HEK293 cells or HPAECs were exposed to growth media (as above)
for 48 h in 0.2% O2. In order to remove cellular debris, conditioned
media were centrifuged at 3,000 ×g for 10 min at 4 °C, and then syringe
ﬁltered (Nalgene, 0.2 μm). Media were then concentrated ~100-fold via
centrifugation through a 100 kDa membrane ﬁlter, per the
manufacturer's instructions (Amicon Ultra-15 Centrifugal Filter Unit
with Ultracel-100 membrane, Millipore). Concentrated conditioned
media were then exposed to Protein A/G magnetic beads conjugated to
anti-AGO2or isotype IgG controlmousemonoclonal antibody (Millipore)
for 4 h at 4 °C, per the manufacturers' instructions (Magna RIP RNA-
Binding Protein Immunoprecipitation Kit, Millipore). After serial washing
of beads, bound protein–miRNA complexes were removed from beads.
Eluant was subjected to immunoblotting to conﬁrm proper immunopre-
cipitation. Separately, miRNA expression in the eluant was assessed by
RNA extraction and RT-qPCR, as described in Supplementary data.
2.5. Exposure of cultured recipient cells to conditioned media
To generate high levels of released miR-210, donor HEK293 cells
were transfected with an expression vector encoding miR-210, plenti-
210 (versus plenti-Cont) and exposed to DMEM media supplemented
with 10% fetal calf serum for 48 h in 0.2% O2. Separately, to enrich
conditioned media with endogenously expressed miR-210, non-
transfected HT-29 cells were exposed to hypoxia (0.2% O2) for 48 h
followed by a 6 h period of reoxygenation (20% O2). Conditioned
media and donor cells were then harvested. Following centrifugation
and syringe ﬁltering of conditioned media as above to remove cellular
debris as above, an equal volume of fresh growth media was added to
conditioned media in order to replenish growth factors and nutrients
after initial conditioning. Immediately afterwards, naive recipientmiR-
210−/− MEF cells cultured in advance in 6-well plates, were then
exposed to these conditioned media (2 ml/well) for 48 h in hypoxia
(0.2%O2) (or continued normoxia as a control). The cellswere harvested
for RT-qPCR analysis, standard immunoblotting, or Complex I enzyme
activity quantiﬁcation, as described below and in Supplementary data.
2.6. Production of HPAEC conditioned media for microvesicle analysis
HPAECs were cultured in 10 mm dishes in 1% FBS containing cell
culture medium in order to minimize serum protein interference with
microvesicle analysis. To ensure that all microvesicles contained in the
conditioned media were derived from source cells, fetal bovine serum
was subjected to ultracentrifugation (100,000 ×g for 2 h) prior to addi-
tion to basal cell culture media. Cells were exposed to either 48 h of
normoxia (20% O2), 48 h of hypoxia (0.2% O2), or 48 h of hypoxia
(0.2% O2) followed by PBS wash, media replacement, and an additional
48 h of reoxygenation (20% O2). Resultant conditioned media was
harvested for microvesicle analysis.
2.7. Separation ofmicrovesicles in culturemedia for subsequent exposure to
recipient cells
Cells and debris were removed from conditionedmedia produced as
described above by differential centrifugation at 400 ×g for 10 min and
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was then subjected to ultracentrifugation at 120,000 ×g for 2 h in order
to deplete the sample ofmicrovesicles. To expose recipient cells to these
fractionated samples and determine delivery of extracellular miRNAs,
the microvesicle-enriched sediments (pellets) were resuspended in a
volume ofmedia equivalent to that of the supernatant. An equal volume
of fresh growth media was added to each sample in order to replenish
growth factors and nutrients after initial conditioning. Media were
then used to culture naïve miR-210−/−MEFs for 48 h.
2.8. MiRNA and protein analysis of fractionated conditioned media
Conditioned media from HPAECs were produced and subjected to
ultracentrifugation at 120,000 ×g for 2 h, as described above. To analyze
the separation of microvesicles by ultracentrifugation, equivalent
volumes of non-ultracentrifuged (non-processed) conditioned media
and ultracentrifuged supernatant were treated with 8.3% polyethylene
glycol 4000 (PEG; Sigma, 89782 250 mM NaCl, 50 mM HEPES (pH 7.2)
at 4 °C for 18 h) to precipitate microvesicles. Immunoblotting for
microvesicle markers was then performed in order to compare
microvesicles present in PEG precipitants with the ultracentrifuged sed-
iments (pellets). Antibodies used to detect microvesicle markers
included: Alix (3A9 clone), Flotillin-1, and CD63 (H-193 clone) (Santa
Cruz Biotechnology). Fibronectin was used as an unrelated control
(Abcam). Thismethodwas previously described in detail [36]. Separate-
ly, to measure miRNAs present in each compartment, equivalent
volumes of non-processed conditioned media and ultracentrifuged su-
pernatant were subsequently concentrated via ultraﬁltration using a
100 kDa cutoff ﬁlter (Amicon Ultra, Millipore). RNAwas then extracted
from both the concentrates and ultracentrifuged sediments for RT-qPCR
analysis.
2.9. Detection of AGO2 complexes in the culture medium
HEK293 cells were co-transfected with plenti-210 along with either
AGO2 WT FLAG or AGO2 P(700)A FLAG constructs. Transfected cells
were incubated for 15 h in normoxia (20% O2) under serum-free condi-
tions. From each condition, 1 ml of media was centrifuged to pellet
cellular debris (12,000 ×g, 10 min) and then incubated overnight with
250 μl of Trichloroacetic Acid (Sigma, T0699) at 4 °C to precipitate the
soluble protein components. To detect AGO2 FLAG-tagged transgenes,
the pelleted precipitates were then immunoblotted with the M2-Flag
mouse monoclonal antibody (Sigma-Aldrich). Intracellular levels of
AGO2 FLAG-tagged constructs were compared in parallel by standard
harvesting and immunoblotting with the M2-Flag mouse monoclonal
antibody. Immunoblot for actin (Sigma-Aldrich) was used as a loading
control for cellular components; Ponceau S stain (Sigma-Aldrich)
was performed for extracellular components.
2.10. P4HA1 knockdown in HPAECs, HEK293 cells, and miR-210−/−MEFs
HEK293 cells or HPAECs were transfected in 6-well plates with
either siRNA speciﬁc for human P4HA1 (20 nM, Santa Cruz Biotechnol-
ogy) or si-Control (20 nM, Santa Cruz Biotechnology). Cells were then
exposed to 48 h of hypoxia (0.2%O2), and cells andmediawere harvest-
ed for RT-qPCR analysis. Separately, recipient MEFs were transfected
similarly with siRNA speciﬁc for mouse P4HA1 (20 nM, Santa Cruz
Biotechnology) or si-Control and were exposed for 48 h of hypoxia
(0.2% O2) to ﬁltered, conditioned media (as described above) derived
from HEK293 cells transfected with plenti-210. Recipient MEFs were
then harvested for RT-qPCR analysis and standard immunoblotting.
2.11. Detection of AGO2 FLAG in recipient miR-210−/−MEF cells
miR-210−/−MEF cells were exposed for 48 h to ﬁltered, conditioned
media (prepared as above) derived from HEK293 cells transfected witheither AGO2WTFLAGorAGO2P(700)A FLAG constructs and conditioned
in hypoxia (0.2%O2) for 48 h. Subsequently,MEF cellswere lysedwith 1%
detergent in PBS (lauryl maltoside, Sigma-Aldrich), and lysates were ex-
posed to Protein A/Gmagnetic beads conjugated to Anti-M2 FLAGmouse
monoclonal antibody (Sigma-Aldrich) for 12 h at 4 °C, as per the
manufacturer's instructions (Magna RIP RNA-Binding Protein Immuno-
precipitation Kit, Millipore). After serial washing of the beads, presence
of FLAG-tagged AGO2 was determined by immunoblotting of the eluant
using the M2 FLAG antibody.
2.12. RNA interference transactivation assays
miR-210−/− MEFs were transfected with either psicheck-ISCU or
psicheck-cont (2 μg/well) in 6-well plates. After 24 h, transfected cells
were exposed to miR-210-enriched conditioned media versus miR-
210-deﬁcient media, as derived from HEK293 donor cells described
above. Cells were then exposed to normoxia or hypoxia for 48 h. Subse-
quently, Renilla luciferase activity and ﬁreﬂy luciferase activity were
quantiﬁed by the Dual Luciferase Assay System (Promega). For each
well, Renilla luciferase activity was normalized to ﬁreﬂy luciferase
activity.
2.13. Complex I activity assay
Cultured cells were lysed in 1% detergent (lauryl maltoside, Sigma-
Aldrich) in PBS for membrane protein extraction. As previously de-
scribed [7], Complex I activity was measured by immunocapture and
spectrophotometry (A340 nm) reﬂecting oxidation of NADH to NAD+,
per the manufacturer's instructions (Mitosciences).
2.14. Statistical analysis
Unless otherwise indicated, all numerical quantiﬁcations represent
mean ± standard error of the mean for three or more independent
experiments, each performed at least in triplicate (N= number of inde-
pendent experimental repetitions). Images are representative of exper-
iments that have been repeated at least three times. Paired samples
were compared by Student's t test. Comparison of multiple samples
was performed by one-way ANOVA followed by Student–Newman–
Keuls post hoc tests to calculate p-values. In the peripheral arterial dis-
ease cohort, a Wilcoxon Rank Sum test was used to analyze non-
normally distributed continuous variables (HDL and triglycerides in
patient samples); a chi-squared test was used to analyze categorical
variables. Error bars reﬂect SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
NS signiﬁes p N 0.05.
2.15. Additional information
See Supplementary data where previously published procedures are
described for RNA extraction fromplasma, conditionedmedia, and cells;
RT-qPCR, immunoblotting, plasmids, antibodies, and standard methods
of transfection of cultured cells, immunoblotting, isolation of MEFs, and
human plasma sampling.
3. Results
3.1.MiR-210 is released frommammalian cells in culture and in vivo during
hypoxia and reoxygenation
We ﬁrst wanted to determine whether a direct causative link exists
between hypoxia, reoxygenation, and the release of miR-210 into the
extracellular space. To do so, based on our prior observations of the ro-
bust actions of miR-210 in primary cultured human pulmonary arterial
endothelial cells (HPAECs) and transformed human embryonic kidney
293 cells (HEK293) [7], these cell types were ﬁrst exposed to normoxia
(20% O2) versus hypoxia (0.2% O2) for 24 h and normoxia versus
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its high levels of reported release [25] but stability of expression in hyp-
oxia. miR-223 was also studied, given its reported transport in HDL-
containing complexes [26]. miR-21was chosen, given its known regula-
tion by hypoxia, especially in HPAECs [37]. Unlike miR-16 or miR-223,
intracellular levels of miR-210, and to a lesser extent intracellular
miR-21, were progressively up-regulated by hypoxia at both time
points and in both HPAECs (Fig. 1A) and HEK293 cells (Fig. 1C).
Mirroring these intracellular levels, extracellular miR-210 levels were
also progressively up-regulated under these conditions (Fig. 1B, D).
Importantly, however, released levels of miR-16, miR-223, and miR-21
were not substantially altered in hypoxia, indicating a speciﬁcity of
miR-210 release in hypoxia.
To determine whether such a linear relationship of intracellular and
extracellularmiR-210 exists during reoxygenation, both cell types were
exposed to normoxia (20%O2) or hypoxia (0.2%O2) for 24 h followed by
media exchange and exposure to normoxia for an additional 24 h.
Intracellular miR-210 was up-regulated by hypoxia but then down-
regulated by reoxygenation in both cell types (Fig. 2A, C). Extracellular
miR-210 levels were also up-regulated during hypoxia in both cell
types (Fig. 2B, D), but notably, released miR-210 expression remained
elevated during reoxygenation, in contrast to the down-regulation of
intracellular miR-210 in that time frame. In contrast, extracellular pat-
terns of expression for miR-16, miR-223, and miR-21 were not similar
to miR-210, again reﬂecting the speciﬁcity of these release patterns.
Similar results of miR-210 release in reoxygenation were found in Intracellular miRNA 
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Fig. 1.MiR-210 is released during hypoxia from human PAECs and HEK293 cells. In contrast to
lesser extent miR-21, in human PAECs (A) and HEK293 cells (C) increased after 24 h of hypoxia
cellularmiR-16, miR-223, andmiR-21 levels, extracellularmiR-210 fromHPAECs (B) and HEK2
of hypoxia. In all panels, for eachmiRNA tested,miRNAexpression after 24 h of normoxiawas as
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, NS signiﬁes p N 0.05.many, but not all (e.g., pulmonary arterial smooth muscle cells), prima-
ry and transformed cell types, with a particularly high level of release
fromHT-29 adenocarcinoma cells (Supplemental Fig. 1). Thus, although
there is some heterogeneity of release depending upon cell context,
speciﬁc mechanisms across multiple cell types exist that similarly regu-
late the release of miR-210 in hypoxia and reoxygenated states and do
not solely reﬂect changes in intracellular miRNA or generalized miRNA
release.
To determine whether extracellular miR-210 is preferentially
released into the circulating blood stream in vivo, two models of physio-
logic and pathophysiologic exposure to hypoxia and ischemiawere char-
acterized in humans. In a cohort of Andeanwomen of 36 weeks gestation
chronically living at altitude (3600–4100 m, La Paz or El Alto, Bolivia),
plasma levels of miR-210 were increased as compared with matched
pregnant Andean controls living at sea level (400 m, Santa Cruz,
Bolivia) (Fig. 3A; subject demographics previously described in [34,35]
with additional parameters summarized in Table S1). Alternatively, circu-
lating levels ofmiR-210were increased in the plasma of humanswith in-
termittent claudication secondary to peripheral artery disease as
comparedwith age/gendermatchedhealthy controls (Fig. 3C; subject de-
mographics summarized in Table S2). In contrast, the brain-enriched
miR-134, which is not hypoxia-responsive, displayed negligible
alterations among these matched cohorts (Fig. 3B, D). As a result,
by analysis of conditioned cell culture media and human plasma, we
have determined that exposure to hypoxia or alterations in oxygen
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extracellular miRNA.3.2. The majority of miR-210 found in the extracellular space is not
contained within microvesicles
Previously, c-miR-210 (circulating or extracellular miR-210) has
been reported within [38–40] and outside of microvesicles [25]. To
determine the relative levels of endogenous packaging of released
miR-210 after hypoxia or reoxygenation, HPAECs cultured in media
containing 1% FBS (previously depleted of microvesicles) were subject-
ed to 48 h of normoxia; 48 h of hypoxia; or 48 h of hypoxia followed by
media replacement and 48 additional hours of reoxygenation. In each
context, conditioned media was subjected to ultracentrifugation
(120,000 ×g for 2 h) (Fig. 4A). By immunoblot, microvesicle markers
were found in the ultracentrifuged pellet and precipitated contents
of the non-ultracentrifuged (non-processed) conditioned media but
not supernatant (Fig. 4C), thus conﬁrming successful separation by
ultracentrifugation. In those samples, a higher proportion ofmiR-223 con-
tent was found in microvesicle-enriched fractions in normoxia and reox-
ygenation, while equivalent levels were observed in both fractions during
hypoxic exposure (Fig. 4B). In contrast, for both miR-16 and miR-210,
a majority of the total miRNA content was present in microvesicle-
depleted fractions in normoxia, hypoxia, and reoxygenation (Fig. 4B).
Thus, while all of thesemiRNAswere found in both fractions, a speciﬁcity
in the patterns of miRNA release was evident, suggesting the existence of
a regulatory system controlling miRNA packaging during exposures to
variable oxygen conditions.3.3. Hypoxia induces release of miR-210 associated with AGO2
Certain circulatingmiRNAs (c-miRNAs) have been described to bind
AGO2 both within and outside of microvesicles [25,41], but a speciﬁc
association between AGO2 and circulating miR-210 has not been
described. Therefore, we analyzed conditioned media from either
HEK293 cells or HPAECs after exposure to hypoxia for 48 h followed
by centrifugal concentration ofmedia using a 100 kDaﬁlter. Concentrat-
ed media was then treated with detergent to release microvesicle con-
tents, followed by co-immunoprecipitation using an α-AGO2 antibody
that was conﬁrmed to pull down AGO2 effectively (Fig. 5A). Released
miR-210, but not releasedmiR-223, co-immunoprecipitated speciﬁcally
in the presence of α-AGO2 as compared with isotype control IgG
(Fig. 5B–C). Thus, from both hypoxic HPAECs and HEK293 cells, miR-
210 is released in association with AGO2.3.4. Intracellular hypoxic activation and extracellular release of miR-210
are conversely regulated by prolyl-hydroxylation of AGO2
Previously, hydroxylation of proline residue 700 of AGO2 was
reported to increase the intracellular activity ofmiRNA for target gene re-
pression [42]. Furthermore, hypoxia speciﬁcally induces such AGO2
prolyl-hydroxylation by induction of the C-P4H(I) prolyl-hydroxylase
[43]. Given the association ofmiR-210with AGO2during extracellular re-
lease, we wanted to determine whether such prolyl-hydroxylation also
inﬂuences miR-210 activity and release in hypoxia. Correlating with
prior observations [43], we observed transcriptional up-regulation of
the alpha subunit of C-P4H(I) (P4HA1) after 24 and 50 h of hypoxia in
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with reoxygenation (Supplemental Fig. 2A–B). siRNA-mediated knock-
down of P4HA1 was also performed (Supplemental Fig. 2C–E) in order
to verify the role of AGO2 prolyl-hydroxylation in miR-210 release. In
HEK293 cells, while intracellular expression of miR-210 was not altered
by siRNA delivery (Fig. 6A), expression of extracellular miR-210 was
increased by P4HA1 knockdown (Fig. 6B) — a result that was especially
evident after comparison to 50 h of hypoxia and endogenous P4HA1
up-regulation with control siRNA. Similarly, knockdown of P4HA1
increased extracellular miR-210 derived from hypoxic HPAECs, but this
was also accompanied by an additional increase of intracellular miR-
210 (Fig. 6C–D). Importantly, similar results were obtained in HPAECs
exposed to less severe hypoxia (2% O2, Supplemental Fig. 3). Thus,
under a range of hypoxic conditions, P4HA1 controls the expression of
extracellular miR-210.
We then wanted to determine whether prolyl-hydroxylation of
AGO2 speciﬁcally regulates the release of miR-210 rather than merely
miR-210 expression. To do so, in HEK293 cells, two types of FLAG-
tagged AGO2 transgenes were overexpressed: wildtype AGO2 and
prolyl(700)-to-alanine hydroxylation mutant AGO2 [42]. In contrast
to the wildtype AGO2 transgene that enabled miR-210-dependent
repression of its direct target ISCU in hypoxia, overexpression of thenon-hydroxylated proline-to-alanine (700) mutant AGO2 reduced the
repressive activity of miR-210, allowing ISCU protein levels to increase
in hypoxia (Fig. 7A). Thus, prolyl(700)-hydroxylation enhances intracel-
lular miR-210 activity for target gene repression. Conversely, while hyp-
oxic induction of intracellular miR-210 expression was comparable in
the presence of either AGO2 transgene, release of miR-210 to the extra-
cellular space was substantially increased by non-hydroxylated mutant
AGO2 expression, particularly evident after 48 h of hypoxia (Fig. 7B).
Importantly, neither AGO2 transgene was expressed at substantially dif-
ferent levels in the intracellular or extracellular space (Fig. 7C). Nonethe-
less, demonstrated by co-immunoprecipitation of the extracellular AGO2
transgene products using an α-FLAG antibody, a higher proportion of
released miR-210 was associated with the non-hydroxylated mutant
as compared with wildtype AGO2 (Fig. 7C). Thus, the regulation of miR-
210 release by AGO2 hydroxylation state does not rely solely upon a
more abundant expression or release of the non-hydroxylated AGO2
itself. Rather, it may inﬂuence the propensity of miR-210 to associate
with AGO2 under various oxygen-dependent exposures. Thus, consider-
ing together these convergent results, prolyl-hydroxylation appears
to act as a molecular switch controlling cellular release of miR-210.
In hypoxia, prolyl-hydroxylation maximizes the intracellular activity
of miR-210 while blunting, but not entirely abrogating, its release. In
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2534 A. Hale et al. / Biochimica et Biophysica Acta 1843 (2014) 2528–2542normoxia and reoxygenation, prolyl-hydroxylation of AGO2 is inhibited,
thus decreasing miR-210 intracellular activity and expediting the trans-
port of excess miR-210 to the extracellular space.
3.5. Released miR-210 is transported into recipient cells, but its metabolic
activity is augmented during hypoxia
To determine deﬁnitively whether extracellular miR-210 can
be transported into recipient cells and to rule out the possibility of
up-regulation of endogenous miR-210 encoded by recipient cells,
miR-210−/− murine embryonic ﬁbroblasts (MEFs) were used asrecipient cells and conﬁrmed to express negligible levels of miR-210
(Fig. 8A). For these experiments, conditioned media replete with
released miR-210 were prepared from HEK293 cells transfected with
an expression plasmid for miR-210 and exposed to hypoxia for 48 h.
Upon exposure tomiR-210−/−MEFs either under normoxic or hypoxic
conditions, intracellular miR-210 levels increased (Fig. 8A), thus dem-
onstrating direct miRNA uptake.
We then wanted to determine whether packaging of released miR-
210 inﬂuences delivery to recipient cells. Conditioned media replete
with released miR-210 from HEK293 cells were ultracentrifuged in
order generate microvesicle-depleted supernatant and microvesicle-
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tioned media from HPAECs (Fig. 4B), a majority of miR-210 was detect-
ed in the microvesicle-depleted supernatant (Fig. 8B). Importantly,
exposure of naive miR-210−/− MEFs to either supernatant or resus-
pended pellet led to delivery of miR-210 (Fig. 8C), thus indicating that
released miR-210 can enter recipient cells despite being packaged out-
side of microvesicles.
To ascertain whether exogenously deliveredmiR-210 is active in re-
cipient cells, ISCU expression and mitochondrial respiratory complex
activity were assessed, as a primary example of a robust target by
which activity of delivered miR-210 can be quantiﬁed and consistent
with the predominant functions of this miRNA [7]. During hypoxia
(Fig. 8D) but less so during normoxia (Supplemental Fig. 4A), ISCU ex-
pression was down-regulated in miR-210−/−MEF cells after delivery
of miR-210. Correspondingly, primarily evident during hypoxia
(Fig. 8E) and less so during normoxia (Supplemental Fig. 4B), did deliv-
ered miR-210 repress luciferase reporter gene expression carrying the
ISCU-speciﬁc miR-210 binding site in its 3′ untranslated region. Finally,
augmented during hypoxia (Fig. 8F), but not normoxia (Supplemental
Fig. 4C), mitochondrial Complex I activity was down-regulated in
MEF cells after exposure to extracellular miR-210. Thus, extracellularmiR-210 can be transported into recipient cells under both normoxic
and hypoxic conditions; however, its metabolic activity is particularly
augmented during hypoxic exposure.
Given the importance of AGO2 prolyl-hydroxylation in the activity
and release of miR-210 in hypoxic “source” cells, we wanted to deter-
mine whether this switch also regulates the actions of delivered miR-
210 in recipient cells. To do so, conditioned media were generated
from HEK293 cells carrying released miR-210 complexed with either
wildtype or (P700A) hydroxylation mutant AGO2. After normalizing
for similar levels of released miR-210, a comparable degree of
miR-210 delivery was achieved in miR-210−/−MEF recipient cells in
the presence of wildtype AGO2 or hydroxylation mutant AGO2
(Fig. 9A). Importantly, as demonstrated by immunoblotting of α-FLAG
immunoprecipitant from recipient cell lysates, exogenously derived
FLAG-tagged AGO2 (~100 kDa) was also detectable in the intracellular
space after delivery of miR-210 (Fig. 9B), indicating that both miR-210
and AGO2 are transported into recipient cells. Yet, while delivery itself
was not affected, we postulated that activity of deliveredmiR-210 is de-
pendent upon AGO2 prolyl-hydroxylation. Consistent with such a theo-
ry, siRNA-mediated knockdown of P4HA1 inmiR-210−/−MEFs during
exposure to miR-210-enriched media blunted the miR-210-dependent
down-regulation of ISCU in hypoxia (Fig. 9C). Similarly, the repressive
effects on ISCU expression by delivered miR-210 in hypoxia were evi-
dent primarily in the presence of delivered wildtype AGO2 but not the
hydroxylationmutant AGO2 (Fig. 9D). Thus, while not directly affecting
uptake of miR-210, AGO2 prolyl-hydroxylation exerts precise control
over delivered miR-210 in recipient tissue by speciﬁcally accelerating
its activity in hypoxia.
Finally, we aimed to determine whether endogenously released
miR-210 is released in sufﬁcient quantities for active uptake by recipient
cells. To do so, HT-29 adenocarcinoma cells, which release relatively
high levels ofmiR-210 (Supplemental Fig. 1),were used to produce con-
ditionedmedia enriched for releasedmiR-210 by exposure to a protocol
of hypoxia-reoxygenation (Fig. 10A). For comparison, conditioned
media without any released miR-210 were harvested from miR-
210−/− MEFs, and conditioned media enriched for miR-210 were
harvested from HEK293 cells expressing a miR-210 transgene. While
miR-210 was undetectable in media derived from miR-210−/−MEFs,
substantial but approximately 10-fold lower levels of extracellular
miR-210were observed inmedia derived fromHT-29 cells as compared
with media from transfected HEK293 cells (Fig. 10A). To determine
whether these lower concentrations of endogenously produced miR-
210 could be delivered to recipient cells, naive miR-210−/− MEFs
were then exposed to HT-29 conditionedmedia andwere subsequently
exposed either to normoxia (20% O2) or hypoxia (0.2% O2) for 48 h. Im-
portantly, within recipient cells exposed to HT-29-conditioned media
but not miR-210−/−MEF-conditioned media, miR-210 was detected
(Fig. 10B). Similar to exposures using conditioned media from
transfected HEK293 cells (Fig. 8), such miR-210 delivery was accompa-
nied by a decrease of ISCU as well as an additional miR-210 target, E2F3
[44], particularly during hypoxic, but not normoxic, exposure of recipi-
ent cells (Fig. 10C–D). Thus, even at lower concentrations, endogenous-
ly released miR-210 is indeed sufﬁcient for uptake and suppression of
miR-210 gene targets in recipient cells.
4. Discussion
Here, we deﬁne a unique molecular communication systemwhereby
miR-210 is released by hypoxic cells and taken up by recipient cells to
regulate adaptive programs inmitochondrial metabolism and potentially
key features related to remote IPC (Fig. 11). In particular, we introduce a
highly speciﬁc regulatory system by which AGO2 prolyl-hydroxylation
not only controls miR-210 activity but also, in a reciprocal fashion, mod-
ulates the release of miR-210. In doing so, our data suggest the presence
of a precisely controlled molecular messaging and depot system — one
that regulates the release, transport, storage, and activation of miR-210
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2536 A. Hale et al. / Biochimica et Biophysica Acta 1843 (2014) 2528–2542in recipient tissue, thus preventing adversemiR-210 activity in normoxia
while still accelerating adaptation in hypoxia.
Post-translational modiﬁcations of AGO2 in general may represent a
major regulatory mechanism by which the cell can rapidly control spe-
ciﬁc circulating miRNAs such as miR-210 under dynamically changing
conditions. For instance, EGF-dependent phosphorylation of AGO2
has been reported as a key switch controllingmicroRNA activity in hyp-
oxia [45]. The additional regulation of released miR-210 by prolyl-
hydroxylation of AGO2 offers substantial teleological advantages by
which mammals may prepare for impending hypoxic injury. Similar to
HIF-1α itself, we have found that miR-210 assumes an adaptive role
during hypoxia but a maladaptive role in normoxia [7]. Thus, of para-
mount importance to tissue homeostasis and survival is to ensure that
miR-210 is activated primarily during hypoxia. In part, this is possible
via the direct regulation of miR-210 expression by HIF-1α binding to
the miR-210 promoter and up-regulation of transcription in hypoxic
tissue [46]. Our current ﬁndings reveal that such precise control can
also be achieved via expediting removal of miR-210 from the intracellu-
lar space in normoxia. Moreover, when miR-210 is delivered to recipi-
ent tissue that has yet to experience hypoxic stress, reduced prolyl-
hydroxylation of AGO2 prevents unnecessary and potentially adverse
activity of this miRNA. Notably, even in the absence of hypoxia, deliv-
ered miR-210 can still carry biological activity, as reported recently
[39,40]. However, especially evident when miR-210 is deliveredin modest amounts, our data demonstrate that hypoxic induction of
AGO2 prolyl-hydroxylation can immediately maximize the adaptive
functions of this miRNA. Thus, mirroring the rapid on-off switch of
HIF-1α accumulation and degradation, we now propose an equally
intricate system for maximizing the control of miR-210 activity in
both source and recipient tissue in order to anticipate and to respond
to hypoxic stimuli.
The inducible properties of miR-210 also allow for an adept function
of shuttling between source and recipient tissue in order to guide opti-
mal adaptation. Notably, the transport of extracellular forms of other
miRNA has been reported in non-hypoxic contexts, yet enthusiasm re-
garding the biological importance of extracellular miRNA in general
has been tempered by the relative inefﬁciency of miRNA import into
recipient cells. Speciﬁcally, in many cases, the repressive functions of
miRNA require higher levels of expression than delivery of extracellular
miRNA can achieve [47]. Furthermore, recipient tissues often already
express substantial levels of endogenous miRNA prior to delivery, thus
decreasing the relevance of slight increases in total intracellular expres-
sion after miRNA uptake. In contrast, the biology of miR-210 circum-
vents those issues. miR-210 is expressed only at relatively low levels
in normoxic contexts [48], and its ability to engage its direct targets
such as ISCU may require as little as 1.5–3-fold up-regulation during
hypoxia [7]. Thus, unlike a number of other miRNAs that appear to
necessitate much higher absolute levels of expression to engage their
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2537A. Hale et al. / Biochimica et Biophysica Acta 1843 (2014) 2528–2542target genes effectively [i.e., miR-21 [37]], delivery of miR-210, even
in modest quantities, is especially suited to prepare normoxic tissue
for incipient hypoxic stress when relatively little endogenous miR-210
is available.
Beyond these speciﬁc implications of our understanding of hypoxic
adaptation, this study substantially clariﬁes aspects of the regulation
and function of released miRNA in hypoxia and provides a necessary
foundation for further exploration. Notably, our data delineate the spec-
iﬁcity by which release of miR-210 is regulated by hypoxia-dependentAGO2-prolyl hydroxylation, but other miRNAs such as miR-16, miR-
223, or miR-21, are not released in the same patterns. MiRNA sequence
could constitute a determinant of such speciﬁcity, as has recently been
demonstrated for exosomal packaging of miRNAs in T-cells by
sumoylation of hnRNPA2B1 [49]. However, it is equally plausible that
the robust transcriptional induction of miR-210 in hypoxia and its ro-
bust down-regulation in reoxygenation may allow the hydroxylation
state of AGO2 to exert greater control over this miRNA. Such a model
could be envisioned whereby actively generated or degraded miRNAs
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2538 A. Hale et al. / Biochimica et Biophysica Acta 1843 (2014) 2528–2542are preferentially transported to subcellular organelles or pathways
that make them more dependent upon association with AGO2 and
shuttling either to target gene engagement or packaging for release.
This latter explanation resonates well with our ﬁndings that AGO2
hydroxylation state can inﬂuence the association of miR-210 with ex-
tracellular AGO2 (Fig. 7C). Clariﬁcation of these possibilities warrantsfuture investigation. Moreover, while much attention has been placed
on miRNA delivery via microvesicle transfer, we now report that some
miRNAs, including miR-210, are primarily released independent of
microvesicles during exposures to various oxygen contents, and these
forms are sufﬁcient for delivery in recipient cells.While somemolecular
pathways that drive exosomal [28] and non-exosomal [26] release have
A B
-Actin
-ISCU
miR-210/
AGO2-WT 
complexes
Hypoxic miR-210 -/- MEFs
Exposure:
miR-210/
AGO2 (P700->A)
complexes
0
5
10
15
20
25
AGO2 (WT)
AGO2 (P700->A)
ISCU Expression
De
ns
ito
m
et
ry
 
(A
rb
itr
ar
y 
U
ni
ts
)
C
miR-210 -/- MEFs
(0.2% O )2
*
ISCU Expression
miR-210 -/- MEFs 
Intracellular miR-210
si-P4HA1 (20% O )
si-Control (20% O )
si-P4HA1 (0.2% O )
si-Control (0.2% O )S N
D
D e
n s
ito
m
et
ry
 
(A
rb
itr
ar
y 
U
ni
ts
)
0
0.5
1
1.5
2
2.5
3
si-P4HA1
si-Control
Normoxia
Hypoxia
++
+
+
+
+
+ +
- -
- -
- -
- -
-FLAG
IP:
miR-210 -/- MEF
c-miR-210+
Non-FLAG
AGO2 (WT)
c-miR-210+
FLAG
AGO2 (WT)
Exposure:
c-miR-210+
FLAG
AGO2 (WT)
FLAG Ab FLAG AbIgG
Control
* *
0
200
400
600
800
Co
py
Nu
m
be
r/1
0
pg
to
ta
lR
NA
Exposure to miR-210/AGO2 (WT)
Exposure to miR-210/AGO2 (P700->A)
NS
2
2
2
2Exposure to miR-210-enriched media
-Actin
-ISCU
100 kDa
α
α
α
α
α
Fig. 9. Status of AGO2 prolyl-hydroxylation determines the activity of deliveredmiR-210 in recipient cells. (A) Delivery ofmiR-210 intomiR-210−/−MEF cells was similar after exposure
of released miR-210 derived from cells expressing either AGO2 (WT) or hydroxylation-deﬁcient mutant AGO2. (B) As shown by immunoblot of anti-AGO2 immunoprecipitant from re-
cipient cell lysate, FLAG-tagged AGO2 (WT) (~100 kDa)was detectable in recipientmiR-210−/−MEF cells after exposure tomiR-210-enrichedmedia. (C) siRNA-mediated knockdownof
P4HA1 inmiR210−/−MEFs during exposure to miR-210-enriched media blunted the down-regulation of ISCU in hypoxia but had a negligible effect on ISCU expression in normoxia.
(D) In miR-210−/− MEFs, the hypoxic repressive effects on ISCU by delivered miR-210 were diminished when miR-210 was released from cells expressing the hydroxylation-
deﬁcient mutant AGO2. Immunoblots are representative of experiments performed at least in triplicate; gel densitometry was normalized to actin levels and compared as arbitrary
units. Error bars reﬂect SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, NS signiﬁes p N 0.05.
2539A. Hale et al. / Biochimica et Biophysica Acta 1843 (2014) 2528–2542been characterized, given our results here of the control of the level of
miR-210 release by AGO2 prolyl-hydroxylation, it remains an intriguing
possibility that other aspects of transport, delivery, and degradation
of extracellular miR-210 may also be inﬂuenced by such a mechanism.
Finally, it is possible that other proteins important in regulating
miRNA activity, such as those in the RNA induced silencing complex
(RISC), may also be associated in the secreted complex. Consequently,
RISC modulation in general may serve as a primary determinant of
both subcellular and extracellular localizations of RNA, and its actions
may extend far beyond controlling gene silencing activity alone.
In addition to our ﬁndings in cultured cells, our data expand the
variety of both physiologic and pathophysiologic conditions in which
circulating levels of miR-210 are induced and maintained. Speciﬁcally,
circulating miR-210 has been reported as up-regulated in both plasma
and urine in clinical conditions where hypoxia and/or HIF expressionpredominate — these include cardiovascular diseases such as chronic
heart failure [50,51] and atherosclerotic disease [52,53], a variety of
human solid tumors [15–19], and transplant rejection [54]. When
considered with the intricate control of miR-210 release and activity
by AGO2 prolyl-hydroxylation, these observations suggest that such
conditions in vivo may exploit the actions of delivered miR-210. If so,
mirroring prior ﬁndings in remote IPC where long-term mitochondrial
function is protected [55–57], effective therapeutic options can be
envisioned, whereby deliveredmiR-210 inhibits mitochondrial respira-
tion during acute phases of hypoxia in order to preserve mitochondrial
integrity and respiratory potential once the ischemic threat ceases. To
date, the most promising approaches in manipulating miRNA function
in vivo entail the use ofmodiﬁed antisense oligonucleotides or plasmids
to inhibit speciﬁc endogenous miRNA (i.e., antagomirs, anti-miRs,
and miRNA sponges) (as reviewed by [58]). Yet, the ability to force
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of an efﬁcient approach to load miR-210 artiﬁcially onto AGO2 com-
plexes for in vivo delivery could improve the protocols for remote
IPC and optimize hypoxic adaptation in a variety of physiologic and
disease-oriented contexts. Such an approach may also synergize well
with other rapidly progressing miRNA delivery technologies, such as
nanoparticles or artiﬁcial microvesicles.
In summary,we describe theAGO2-dependent release and uptake of
miR-210 as a unique messaging system designed to facilitate hypoxic
communication across anatomically distinct cells. It may be a key ﬁnd-
ing in understanding the physiological integration of how complex or-
ganisms detect and respond to hypoxic stress. These data should serve
as a foundation for studies designed to explore further other hypoxia-
induced extracellular miRNAs and how these molecules may synergizewith the actions of miR-210. Additionally, these results offer valuable
insights for therapeutic development of extracellular miRNAs for accel-
erating adaptation to hypoxia and ischemia in a wide variety of human
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